🦋 让 amivantamab + lazertinib 更安全：#ESMO26 的 COCOON 新数据！
COCOON 研究的新结果表明，简化皮肤预防措施联合皮下注射 amivantamab + lazertinib，可能大幅减少一线 EGFR 突变型 NSCLC 的治疗相关皮肤毒性。关键发现：≥2 级皮肤 AE：标准启动方案为 39%，而 lazertinib 1 周期导入方案为 18%。简化预防措施似乎可提供与原 COCOON 方案相当的保护作用。SC 可显著减少 IRR 反应。新队列并非随机分组， 不同启动策略之间的比较属于探索性分析。
个人看法：毫无疑问，ami 用得更少，毒性也更低。问题在于，在 Flaura2 时代，疗效是否仍能保持不变？！
#ESMOAmbassador #ESMO26 #LungCancer #NSCLC #EGFR #COCOON #Oncology #CancerResearch
10 浏览 · 1 赞 · 1 转发 · 0 回复
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.org- **标题 / Title：** A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
https://esmocongress.esmo.org- **标题 / Title：** A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
https://esmocongress.esmo.org来源：Alfredo Addeo MD · x.com